Inato is an Artificial Intelligence company that helps life science companies accelerate recruitment in their clinical trials by making data-informed decisions.
Inato matches clinical trials with qualified sites worldwide and optimizes site performance throughout the trial.
Inato was founded in Jan 1, 2016 by Kourosh Davarpanah, William Pambrun, Jean-David Zeitoun, and Philippe Ravaud. The company is headquartered in Paris, France, with offices in New York and London.
Inato helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials by discovering untapped research site potential.
Inato’s platform matches the best sites for any given study and ensures that sites are successfully delivering trials. The platform is built with doctors and for doctors—to navigate the hurdles of today’s increasingly complex research environment.
Inato has partnered with biopharma companies to create an extensive dataset of historical site performance covering 1,500 studies, 17,000 sites and 700,000 patients across 80+ countries. The company has also helped biopharmaceutical companies and clinicians across more than 2,000 research sites and over 50 global trials.
Inato is backed by Obvious Ventures, Cathay Innovation, Serena and Fly Ventures. The company raised $14M in a Series A round on Feb 04, 2020. This brings Inato's total funding to $17M to date.